A Randomized Double-Blind Active-Comparator-ontrolled Parallel Group Study to Evaluate the Safety of Etoricoxib in Osteoarthritis or Rheumatoid Arthritis

Grants and Contracts Details

StatusFinished
Effective start/end date9/13/022/28/07

Funding

  • Merck and Company Inc: $42,434.00